Wu compared XZK plus BGLD versus BGLD, to treat diabetic hyperlipemia; the result shows that XZK can significantly improve the insulin sensitive index (P < 0.01), while the basic treatment group has no significant change, which indicates that XZK can treat insulin resistance in type 2 diabetes patients [21]. This evidence concerns the gene INS and type 2 diabetes mellitus.